Catalog record · Data & Analytics
Stage as of Feb 12, 2024 · historical report, not live reconfirmation.
Pfizer clinical-data review and reconciliation
Vendor workflow source. A reviewed supplier account names the customer and workflow. Supplier attribution and deployment claims are not independent outcome validation.
Last researched Oct 26, 2026. Source access and reported stage are recorded below; deployment evidence does not establish ROI.
What the research supports
Pfizer used SDQ to automate trial-data review and expanded its agreement to extend the workflow across its study portfolio.
- Reported stage
- Production
- Technology
- Other supported technology
- Business function
- Back Office
- Impact (legacy label)
- Not labeled
- Catalog date · unconfirmed
- Not reported
- Imported
- Oct 29, 2026
- Last researched
- Oct 26, 2026
Measures & evidence
No quantified measure recorded. This is a gap in the evidence, not a finding of no value.
Documented vendor relationships
No vendor relationship has been linked to this specific workflow in the curated overlay. This does not mean it was built without vendors.
See the company’s documented relationshipsDeployment evidence & limits
2024 joint/vendor announcement describes an operational collaboration begun in 2020 and plans to continue scaling SDQ. Status as of 2024-02-12.
Stage is as reported in the cited evidence. Current operating status has not been independently reconfirmed; the research date is an editorial review date.
The additional BRAIN submission workflow is described as an expansion opportunity; it is not treated here as an already scaled separate deployment. Vendor release with named Pfizer executive quotation; AI model family and validated accuracy not disclosed. Need source lineage, exception adjudication and checks for changed schemas. Expanded contract scope is not proof of completed global deployment.
Potential FS application · inferred
Inferred: Reconcile regulatory-reporting data across source systems and flag inconsistent or missing loan/transaction records for analysts.
Combines data standardization and AI-assisted quality review before a governed reporting cutoff.
Original industry: Pharmaceuticals and biotechnology. Transfer limits: Need source lineage, exception adjudication and checks for changed schemas. Expanded contract scope is not proof of completed global deployment.
Recorded dependencies
- Traceable source data and approved document/control schemas
- Qualified human review and local testing of accuracy, omissions and full workflow effort
Source register
- Saama and Pfizer Expand Agreement to Integrate AI-Driven Data Solutions Across R&D Portfoliosaama.com · opens in a new tab
Saama · vendor-case · full-text · Published 2024-02-12
Research lanes: health_life_sciences · Batch global-discovery-2026-10-26. Coverage and remaining gaps